Meanwhile, on the BSE, the stock listed at ₹91. The listing price was at par with the issue price of the IPO.
The listing was in line with grey market premium (GMP), where the shares quoted a premium of 1%, which indicated muted listing.
The ₹121 crore IPO, which was open for bidding from August 26 to August 29, was subscribed nearly 7 times overall. The company raised ₹121.03 crore through this IPO.
The company offered a fresh issue of 1.33 crore equity shares at a price band of ₹86-91.
The IPO proceeds will be deployed for expansion of manufacturing facilities, repayment of certain borrowings, and general corporate purposes.
Anlon Healthcare manufactures high-purity pharma intermediates and APIs used in pharmaceuticals, nutraceuticals, personal care, and veterinary products. The company is one of the few Indian manufacturers of Loxoprofen sodium dihydrate, a widely used pain-relief API approved by regulators in Brazil, Japan, and China.
Anlon Healthcare has a diverse portfolio of 65 commercialised products, 28 in the pilot stage, and 49 under validation. It has also entered custom manufacturing of complex chemicals, a high-margin, niche segment.
The company’s capacity utilisation climbed to 84% in FY25, up from just 38% in FY24, highlighting operational efficiency. Plans are in place to expand capacity from 400 MTPA to 1,100 MTPA, positioning the company for future growth.
The issue was managed by Interactive Financial Services with KFin Technologies as the registrar.
